AMSTERDAM, March 5, 2026 /PRNewswire/ -- Norgine, a leading European specialty pharmaceutical company, today announced a new £23 million investment in its Hengoed, Wales manufacturing site bringing the total investment at the facility to more than £50 million since 2022.
Supported by the UK Government's Life Sciences Innovative Manufacturing Fund (LSIMF), this latest commitment will enable further innovation and expansion at the Hengoed site. The investment will strengthen Norgine's ability to reliably supply much-needed medicines across the UK and Europe at a time of increasing global supply chain volatility, while creating 44 new skilled jobs and reinforcing the organisation's long term manufacturing capability in the region. This will be achieved through expanded production and warehousing space, the introduction of high speed, energy efficient manufacturing processes and enhanced quality control capabilities.
Secretary of State for Wales, Jo Stevens said:
"We have a thriving life sciences sector in Wales, and this investment from Norgine is a vote of confidence in our Welsh workforce. I am delighted that UK Government funding is supporting the business to continue to grow and create new well-paid jobs. Norgine is a brilliant example of an international business that is flourishing in Wales."
Saulo Martiniano, Chief Operating Officer at Norgine, said:
"At Norgine, we believe every scientific breakthrough should be able to reach the patients who need it, and innovative approaches to manufacturing and supply are a vital part of making that possible. By expanding and further enhancing our Hengoed facilities, we are increasing capacity, strengthening quality capabilities and investing in more energy‑efficient production. We are proud of this investment, which will help bolster the resilience of UK and European health systems. With the enhanced capabilities at Hengoed, Wales, alongside our site in Dreux, France, and our broad network of manufacturing partners across Europe, we are well placed to navigate uncertainty and deliver medicines efficiently and consistently for years to come."
This £23 million expansion forms part of a broader, long-term commitment to Hengoed. Since 2022, Norgine has invested more than £50 million at the site to enhance operations through capacity expansion and international manufacturing partnerships, such as Japan. Further investments are planned over the coming years which will result in a more resilient supply chain and more than 75 new permanent manufacturing, quality and warehouse roles in Wales.
Established manufacturing network built for resilient supply with ability to scale
Norgine's manufacturing and supply capabilities are designed to scale with demand, supporting resilient access across Europe and beyond. The company's manufacturing infrastructure is underpinned by 60 years of expertise, with specialist engineering and systems design capabilities, supporting the production of medicines for gastrointestinal, rare and specialty conditions from both Norgine's own portfolio and selected in‑licensing partners across Europe and beyond.
Investing in skills and giving back to the community
Norgine is strengthening its long‑term commitment to the region through education and skills initiatives, including student placements with Cardiff University and apprenticeship pathways with local colleges, helping to equip the next generation of manufacturing talent.
The Hengoed site is home to more than 600 skilled employees and currently supplies around 50 million packs of medicines and medical devices each year. Powered by 100% low‑carbon electricity, the facility reflects Norgine's commitment to sustainable manufacturing as it scales.
About Norgine
Norgine is a mid-sized EU-based pharmaceutical company with 1,500 employees, generating approximately €650 million in annual sales. At Norgine, innovation drives our mission to deliver medicines that change lives. From common conditions like constipation to rare and severe diseases such as childhood cancer, we target unmet medical needs because we believe that every scientific breakthrough deserves to reach patients in need.
We use our innovative development, commercialisation and manufacturing capabilities as well as strategic partnerships to navigate complex pathways. Combined with our extensive history and deep regional expertise, this approach allows us to accelerate and expand the reach of life-changing medicines across Europe, Australia, and New Zealand.
We are guided by the trust that healthcare professionals and patients place in us and remain committed to delivering innovation that transforms lives, one patient at a time.
Logo - https://mma.prnewswire.com/media/2846726/5836954/Norgine_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/norgine-announces-23-million-new-investment-as-part-of-more-than-50-million-committed-to-expanding-medicines-manufacturing-in-wales-302704487.html
Ein Berliner Gericht hat die Weitergabe personenbezogener Daten von in Deutschland ansässigen WhatsApp-Nutzern an Facebook für rechtswidrig erklärt und dem Messengerdienst eine entsprechende Übermittlung untersagt. Nach dem Urteil des Landgerichts Berlin II darf WhatsApp darüber hinaus auch jene Kontaktdaten, die im Account der Nutzer gespeichert sind und Personen betreffen, die den Dienst selbst nicht verwenden, nicht an Facebook weitergeben. Geklagt hatte der Verbraucherzentrale Bundesverband (vzbv), der sich gegen Änderungen der Nutzungsbedingungen und der Datenschutzrichtlinie aus dem Jahr 2016 wandte.
Der vzbv hatte in dem Verfahren zusätzlich verlangt, bereits übermittelte Daten löschen zu lassen. Diesen weitergehenden Forderungen folgte die Zivilkammer nicht. Sie verwies darauf, dass WhatsApp erklärt habe, „nie Daten an Facebook als Verantwortlichen weitergegeben zu haben“. Konkrete Anhaltspunkte, die diese Darstellung widerlegen könnten, legten die Verbraucherschützer nach Gerichtsangaben nicht vor. Nutzer waren im August 2016 per Hinweis auf der Website und via Push-Nachricht über die Änderung der Bedingungen informiert und um Zustimmung gebeten worden.
Eine zentrale Rolle spielte in dem Verfahren eine bereits 2016 erlassene Anordnung des Hamburgischen Beauftragten für Datenschutz und Informationsfreiheit. Diese untersagte Facebook am 23. September 2016, personenbezogene Daten deutscher WhatsApp-Nutzer zu erheben und zu speichern. Im Prozess führte der Rechtsvertreter von WhatsApp aus, man habe daraufhin darauf verzichtet, entsprechende Daten in der Europäischen Union mit Facebook zu teilen. Das Berliner Gericht stützte sich in seiner Entscheidung auf diese Darlegung und die fehlenden gegenteiligen Belege der Klägerseite.
Trotz der teilweisen Zurückweisung der Klage bewertet der vzbv das Urteil als Erfolg. Verbandsvorständin Ramona Pop begrüßte insbesondere die Klarstellung des Gerichts, dass eine Einwilligung zur Verknüpfung persönlicher Daten nicht „erschlichen“ werden dürfe. Aus Sicht des Verbands versuchten Meta und andere Plattformen weiterhin, ihre Marktmacht auszubauen und Zustimmungen zur Datenverknüpfung mit aus Verbraucherschutzsicht fragwürdigen Methoden zu erlangen. Der Messengerdienst WhatsApp gehört seit 2014 zum Meta-Konzern, der die Integration seiner Dienste und Datenbestände in den vergangenen Jahren schrittweise vorangetrieben hat.
